3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Other neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Precancerous Conditions
1
Neoplasms
1
Keratosis, Actinic
1
Keratosis
1
Interventions
Gemcitabine
2
Aminolevulinic Acid
2
toripalimab
1
tirbanibulin
1
ruxolitinib
1
potassium oxonate
1
penpulimab
1
human papillomavirus vaccine, L1 type 16, 18
1
gimeracil
1
apatinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Toremifene
1
Tegafur
1
Robotic Surgical Procedures
1
Rifampin
1
RAD140
1
Pregnancy Tests
1
Pemetrexed
1
ON 01910
1
Nivolumab
1
Itraconazole
1
Irinotecan
1
Injections
1
Infusions, Intravenous
1
Hysterectomy
1
Human Papillomavirus DNA Tests
1
High-Intensity Focused Ultrasound Ablation
1
Excipients
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
tirbanibulin
×
Other neoplasm
×
Clear all
NCT06135415
2026-03-25
TirbAKare
Almirall, S.A.
Phase 3
Completed
280 enrolled